- Home
- HBNC vs IOVA Comparison
HBNC vs IOVA Comparison
Compare HBNC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- IOVA
- Stock Information
- Founded
- HBNC 1873
- IOVA 2007
- Country
- HBNC United States
- IOVA United States
- Employees
- HBNC N/A
- IOVA N/A
- Industry
- HBNC Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HBNC Finance
- IOVA Health Care
- Exchange
- HBNC Nasdaq
- IOVA Nasdaq
- Market Cap
- HBNC 826.6M
- IOVA 975.1M
- IPO Year
- HBNC N/A
- IOVA N/A
- Fundamental
- Price
- HBNC $16.12
- IOVA $2.48
- Analyst Decision
- HBNC Buy
- IOVA Buy
- Analyst Count
- HBNC 3
- IOVA 11
- Target Price
- HBNC $19.67
- IOVA $10.50
- AVG Volume (30 Days)
- HBNC 357.8K
- IOVA 21.3M
- Earning Date
- HBNC 10-22-2025
- IOVA 11-06-2025
- Dividend Yield
- HBNC 4.00%
- IOVA N/A
- EPS Growth
- HBNC N/A
- IOVA N/A
- EPS
- HBNC N/A
- IOVA N/A
- Revenue
- HBNC N/A
- IOVA $250,425,000.00
- Revenue This Year
- HBNC $51.78
- IOVA $65.15
- Revenue Next Year
- HBNC $7.40
- IOVA $58.47
- P/E Ratio
- HBNC N/A
- IOVA N/A
- Revenue Growth
- HBNC 1.91
- IOVA 175.62
- 52 Week Low
- HBNC $12.70
- IOVA $1.64
- 52 Week High
- HBNC $19.18
- IOVA $9.70
- Technical
- Relative Strength Index (RSI)
- HBNC 53.29
- IOVA 58.39
- Support Level
- HBNC $15.95
- IOVA $2.08
- Resistance Level
- HBNC $16.44
- IOVA $2.74
- Average True Range (ATR)
- HBNC 0.34
- IOVA 0.22
- MACD
- HBNC 0.04
- IOVA 0.05
- Stochastic Oscillator
- HBNC 66.51
- IOVA 73.47
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.